Vesteck Inc provides advanced solutions for endograft fixation in the healthcare industry, self-described as revolutionizing the industry.

VESTECK, Inc

Vesteck Inc

VESTECK, Inc | 429 followers on LinkedIn. Discover why endovascular clinicians around the world are excited about the VESTECK, &quot;SUTURE-TIGHT&quot; tm catheter. | The &quot;SUTURE-TIGHT&quot; tm catheter secures endovascular aortic repair grafts to the aorta at the time of initial implant or during repair procedures.  (EVAR/TEVAR/TAVR)  
The &quot;SUTURE-TIGHT&quot; tm device is not commercially available.

Ted Wulfman

Sr Director, RA/QA at Vesteck, Inc.

Terrie Heidemann

Senior R&D Engineer at Vesteck Inc

Kenneth Stalker

Manufacturing Technician at Vesteck, Inc

Michaela Murray

"SUTURE-TIGHT"tm presentation by Dainis Krievins, MD, PhD at Frank Veith Symposium 2024 NYC

"VESTECK, Inc. is excited to announce a follow-on investment from Series A investors as it pursues $16M Series B preferred equity. Series B will be used to complete the100 patient, FDA 510K clinical trial." "Our Series A investors, have had the opportunity to closely follow our success. Clearly with this recent investment, they are endorsing the technology and the many milestones we have achieved here at VESTECK," commented VESTECK CEO Joe Rafferty. Next week, VESTECK, Inc will be presenting at the LSI Europe in Lisbon Portugal www.VESTECK.com

Patients, Physicians and Payors want to improve the durability of EVAR/TEVAR procedures. Global population over 65 is increasing, combined with a sedentary lifestyle, increased CV disease, WHO says 23% global population still smokes, the transition of aortic tissue from elastin to collagen are all significant contributors to a growing aortic repair market.

VESTECK Wins!! VESTECK, Inc. and the "SUTURE-TIGHT"tm catheter were selected the top innovative technology in the LIFE SCIENCES TRACK at the inaugural Venture Forum. "SUTURE-TIGHT"tm is a platform catheter, preloaded with NITINOL sutures. Physicians around the world tell us they will use these sutures in the aortic repair space, structural heart, peripheral vascular/venous and general surgical markets. Clinicians have asked VESTECK and "SUTURE-TIGHT"tm to initially target the aortic repair space. The peer reviewed literature documents that EVAR/TEVAR patients will benefit from increased durability and aneurysm sac shrinkage. Kyto Technology and Life Science Inc successfully launched their first innovator/investor conference via virtual presentations and a virtual partnering platform.

Trick question: What do Sean Lyden , Dainis Krievins, MD, PhD , Venkatesh Ramaiah MD, FACS , Dai Yamanouchi , Bao Bui , Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi) , Shannon Dean Thomas , Andrew Holden , Dan Clair , David H. Deaton, MD FACS all have in common? Answer: They have all successfully used the "SUTURE-TIGHT"tm catheter and implanted nitinol sutures, securing endovascular grafts. Their goal, eliminate endoleaks and migration, improving durability, reducing the frequency of complex, expensive EVAR/TEVAR repair procedures. 14 successful clinical implants and 15 successful preclinical studies.

Clinicians recognized the value "SUTURE-TIGHT" brings to patients and payors early on..... we sincerely appreciate it when a financial market leader like BMO highlights the VESTECK, 'SUTURE-TIGHT" technology!

Possibly, clinicians are sending a clear message about the VESTECK, "SUTURE-TIGHT"tm technology during the largest Vascular Conference in the world! The organizing physicians at Charring Cross 2024 have graciously selected the VESTECK, Inc "SUTURE-TIGHT"tm technology to be presented in two ultra high profile sessions. https://lnkd.in/e5QVTDy Professor Andrew Holden will present "SUTURE-TIGHT"tm in the Juxtarenal Controversies session, Thursday 4/25 at 9:10AM. Then during the Innovation Showcase' highly competitive "DRAGON'S DEN," "SUTURE-TIGHT"tm will be presented at 5:35PM, in hopes of winning the coveted top prize. Am I sensing a theme here, clinicians want to discuss "SUTURE-TIGHT"tm?

The VESTECK "SUTURE-TIGHT"tm platform. 1) Clinicians identified a significant global need. 2) Engineers developed a very easy to use over-the -wire catheter. 3) Patients, Clinicians and Payors benefit. 4) 14 cases were successfully performed by 8 different clinicians. Sean Lyden, Venkatesh Ramaiah MD, FACS, Bao Bui, Dainis Krievins, MD, PhD, Dai Yamanouchi, Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi), Andrew Holden, Shannon Dean Thomas 5) Did I mention that we were stacking patents on top of patents? #Moretocome .

VESTECK, INC is very proud to share the news! The United States Patent Office has issued the "REMOTE SURGICAL SUTURE SYSTEM" patent, providing a 20 year runway for this platform technology. Physicians tell us this device platform, used for EVAR and TEVAR, will become the standard of care for all implants. Congratulations Dr. Edoga, Dr. Richard, Ted Wulfman and Kent Stalker! Wonderful work!

VEST

COM:VESTECK

Vesteck Inc

locale

market

industry

website

crunchbase

linkedin

competitor of

Metrics